265 related articles for article (PubMed ID: 29221688)
21. Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.
Wiesweg M; Reis H; Köster T; Goetz M; Worm K; Herold T; Paul A; Dechêne A; Schumacher B; Markus P; Virchow I; Kostbade K; Wolf N; Zaun G; Metzenmacher M; Schmid KW; Schuler M; Kasper S
Clin Colorectal Cancer; 2018 Jun; 17(2):e331-e352. PubMed ID: 29526493
[TBL] [Abstract][Full Text] [Related]
22. Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location.
Golan T; Urban D; Berger R; Lawrence YR
Cancer; 2013 Aug; 119(16):3084-91. PubMed ID: 23720150
[TBL] [Abstract][Full Text] [Related]
23. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.
Sasaki K; Andreatos N; Margonis GA; He J; Weiss M; Johnston F; Wolfgang C; Antoniou E; Pikoulis E; Pawlik TM
J Surg Oncol; 2016 Dec; 114(7):803-809. PubMed ID: 27792291
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
25. Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
Takada S; Sagawa T; Fujikawa K; Tahatsu K; Fukai Y; Hashishita H; Takahashi Y; Endo M
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2325-2330. PubMed ID: 30141310
[TBL] [Abstract][Full Text] [Related]
26. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
27. Influence of primary site on metastatic distribution and survival in stage IV colorectal cancer.
Suthananthan AE; Bhandari M; Platell C
ANZ J Surg; 2018 May; 88(5):445-449. PubMed ID: 28512795
[TBL] [Abstract][Full Text] [Related]
28. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.
Byun JH; Ahn JB; Kim SY; Kang JH; Zang DY; Kang SY; Kang MJ; Shim BY; Baek SK; Kim BS; Lee KH; Lee SI; Cho SH; Sohn BS; Kim S; Hwang IG; Nam EM; Seo BG; Oh SC; Lee MA; Lee SC; Hong JH; Park YS
Korean J Intern Med; 2019 Jan; 34(1):165-177. PubMed ID: 29172407
[TBL] [Abstract][Full Text] [Related]
29. Primary tumor resection with or without metastasectomy for left- and right-sided stage IV colorectal cancer: an instrumental variable analysis.
Yao YC; Chen JQ; Yin L; Lin WH; Peng JH; Fan WH
BMC Gastroenterol; 2022 Mar; 22(1):114. PubMed ID: 35264117
[TBL] [Abstract][Full Text] [Related]
30. The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis.
Blakely AM; Lafaro KJ; Eng OS; Ituarte PHG; Fakih M; Lee B; Raoof M
J Surg Res; 2020 Apr; 248():20-27. PubMed ID: 31841733
[TBL] [Abstract][Full Text] [Related]
31. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer.
Malakorn S; Ouchi A; Hu CY; Sandhu L; Dasari A; You YN; Kopetz ES; Ellis LM; Chang GJ
Clin Colorectal Cancer; 2021 Mar; 20(1):e53-e60. PubMed ID: 33004292
[TBL] [Abstract][Full Text] [Related]
32. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.
Gibbs P; Heinemann V; Sharma NK; Taieb J; Ricke J; Peeters M; Findlay M; Robinson B; Jackson C; Strickland A; Gebski V; Van Buskirk M; Zhao H; van Hazel G;
Clin Colorectal Cancer; 2018 Dec; 17(4):e617-e629. PubMed ID: 30033117
[TBL] [Abstract][Full Text] [Related]
33. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?
Price TJ; Beeke C; Ullah S; Padbury R; Maddern G; Roder D; Townsend AR; Moore J; Roy A; Tomita Y; Karapetis C
Cancer; 2015 Mar; 121(6):830-5. PubMed ID: 25377235
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
[TBL] [Abstract][Full Text] [Related]
35. Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital.
Magaji BA; Moy FM; Roslani AC; Law CW
BMC Cancer; 2017 May; 17(1):339. PubMed ID: 28521746
[TBL] [Abstract][Full Text] [Related]
36. Right colon cancer: Left behind.
Gervaz P; Usel M; Rapiti E; Chappuis P; Neyroud-Kaspar I; Bouchardy C
Eur J Surg Oncol; 2016 Sep; 42(9):1343-9. PubMed ID: 27178778
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy].
He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537
[TBL] [Abstract][Full Text] [Related]
38. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
39. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
40. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
